Kazia Therapeutics Presents Selected Clinical Data From Ongoing Phase 1 Clinical Trial Evaluating EVT801 In Patients With Advanced Solid Tumours
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics has presented selected clinical data from its ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours. The data was presented at a scientific conference.
October 23, 2023 | 11:54 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kazia Therapeutics' ongoing Phase 1 clinical trial of EVT801 could potentially impact the company's stock depending on the results of the trial.
The ongoing Phase 1 clinical trial of EVT801 by Kazia Therapeutics is a significant event for the company. The results of the trial could potentially impact the company's stock. Positive results could lead to an increase in the stock price, while negative results could lead to a decrease. However, as the trial is still ongoing, it is too early to predict the outcome.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100